Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
about
Recent advances in treating Parkinson's disease.Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.Critical Dysphagia is Common in Parkinson Disease and Occurs Even in Early Stages: A Prospective Cohort Study.Drooling is no early sign of dysphagia in Parkinson's disease.Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
P2860
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@ast
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@en
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@nl
type
label
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@ast
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@en
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@nl
prefLabel
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@ast
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@en
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@nl
P2860
P921
P356
P1476
Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide
@en
P2093
Margherita Torti
P2860
P304
P356
10.2147/DDDT.S77749
P407
P5008
P577
2016-02-05T00:00:00Z